Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Hercules Capital Announces Fourth Quarter and Full-Year 2017 Financial Results and Quarterly Distribution of $0.31 per Share
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today... 
From Business Wire News Releases
Hercules Capital Achieves More Than $880 Million in New Commitments in 2017(1)
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital... 
From Business Wire News Releases
Cempra Announces Preliminary Results of 2017 Stockholder Vote
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the... 
From GlobeNewswire News Releases
Hercules Announces Third Quarter 2017 Financial Results and Declares a $0.31 per Share Quarterly Distribution
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today... 
From Business Wire News Releases
Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization
Melinta Therapeutics, Inc., a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, and Cempra, Inc. (Nasdaq:CEMP) today announced the executive... 
From GlobeNewswire News Releases
Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company
Melinta Therapeutics, Inc., a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, and Cempra, Inc. (Nasdaq:CEMP) today announced that their... 
From GlobeNewswire News Releases
How The Parts Add Up: FTXH Targets $25
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Melinta Therapeutics Announces FDA Clearance of Antimicrobial Susceptibility Tests Concurrent with Baxdela Launch in the United States
Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today the U.S. Food and Drug Administration (FDA) has... 
From GlobeNewswire News Releases
3 Companies Tackling the Antibiotic-Resistant Bacteria Crisis
Tags NBRV PRTK CEMP
From Motley Fool
Melinta Therapeutics Publication Reinforces Baxdela Tolerability and Activity in Patients with MRSA Infections and Challenging Comorbidities
Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that results from the company’s first... 
From GlobeNewswire News Releases
The CEMP Paradox: Analysts Bearish But Forecast 91.45% Gains
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Cempra Inc (CEMP). The average 12-month price target for CEMP averaging the work of 5... 
Tags ETFs
From ETF Channel
Commit To Buy Cempra At $2.50, Earn 15.4% Annualized Using Options
Investors eyeing a purchase of Cempra Inc (CEMP) stock, but cautious about paying the going market price of $3.15/share, might benefit from considering selling puts among the alternative strategies at... 
Tags Stocks
From Market News Video
Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that a Phase 1 clinical study of... 
From GlobeNewswire News Releases
Melinta Therapeutics Presents Outcomes of Baxdela Treatment of Gram-Positive and Gram-Negative Pathogens at IDWeek
Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced nine poster presentations and an oral... 
From GlobeNewswire News Releases
Hercules Capital Provides Interim Portfolio Update for Q3 2017
Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company to innovative venture growth, pre-IPO and M&A stage companies backed by leading venture capital... 
From Business Wire News Releases
BRIEF-Cempra and Melinta announce expiration of Hart-Scott-Rodino waiting period for proposed merger
* Cempra and Melinta announce expiration of Hart-Scott-Rodino waiting period for proposed merger 
Tags companyNews
From Reuters: Company News
Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Merger
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the... 
From GlobeNewswire News Releases
Analysts Forecast 24% Gains Ahead For The Holdings of FTXH
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
18 Biggest Mid-Day Gainers For Wednesday
RYB Education, Inc. (NYSE: RYB) shares rose 41 percent to $26.10. RYB Education prices IPO at $18.50 per share. iCAD Inc ... 
Tags Analyst Ratings MU VERU
From Benzinga
25 Stocks Moving In Wednesday's Pre-Market Session
Gainers China Auto Logistics Inc (NASDAQ: CALI) gained 15.8 percent to $2.42 after gaining 0.48 percent on ... 
Tags Losers Markets IZEA
From Benzinga
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios
Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that the commercialization and distribution agreement with... 
From GlobeNewswire News Releases
Melinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
Melinta Therapeutics, a privately held company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that it will be making nine poster presentations and... 
From GlobeNewswire News Releases
Melinta Therapeutics to Participate in Two Upcoming Investor Conferences
Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that it will be presenting at the following upcoming... 
From GlobeNewswire News Releases
Here's Why Nabriva Therapeutics PLC Is Soaring Today
Tags CEMP NBRV
From Motley Fool
That's Odd: Bearish CEMP Analysts See 80.65% Upside
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Cempra Inc (CEMP). The average 12-month price target for CEMP averaging the work of 5... 
Tags ETFs
From ETF Channel
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a boutique securities firm headquartered at the Empire State Building in New York City, is investigating Cempra, Inc.... 
From PR Newswire
Cempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the... 
From GlobeNewswire News Releases
Analysts See 18% Upside For UBIO
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The CEMP Paradox: Analysts Bearish But Forecast 82.11% Gains
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Cempra Inc (CEMP). The average 12-month price target for CEMP averaging the work of 5... 
Tags ETFs
From ETF Channel
BRIEF-Cempra Inc - merger ?agreement with Melinta provides for payment of termination fee of $7.9 mln by each co
* Cempra inc - merger ?agreement with Melinta provides for payment of termination fee of $7.9 million by each co to other party upon termination of merger? Source text: (http://bit.ly/2fw7axx) Further... 
Tags companyNews
From Reuters: Company News
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.